Hanmi Pharmaceutical Co., Ltd.
- Address: 14, Wiryeseong-daero, Songpa-gu, Seoul, Republic of Korea
- Website: www.hanmipharm.com/main.hm
- RnD-centric Biopharmaceutical Company
Hanmi Pharmaceutical is a representative Korean RnD-centric biopharmaceutical company established in 1973 by pharmacist Sung-ki Lim. We plow ahead in pursuing innovation based on our founders conviction as represented by his words, Lets use our technology to make better medicines and his management philosophy of Respect for humanity and Value Creation.
_1st_Highest Number of Open Innovation Achievements Highest Number of Independently Developed Innovative Products among Korean Biopharmaceutical Companies.
_26+_Highest Number of Breakthrough New Drug Pipelines in Korea
_4.5Trillion won_Cumulative RnD Investment
_ AAA in CP Rating_First and Only among participating companies in Korea
- Hanmi is a Pioneer
No path started as a path. Today Hanmi became the protagonist in the development history of the Korean biopharmaceutical industry.
First, Most, and Largest are the indicators that compress the key performance of Hanmi, overwhelming the indutry.
Hanmi Pharmaceutical is a representative Korean RnD-centric biopharmaceutical company established in 1973 by pharmacist Sung-ki Lim. We plow ahead in pursuing innovation based on our founders conviction as represented by his words, Lets use our technology to make better medicines and his management philosophy of Respect for humanity and Value Creation.
_1st_Highest Number of Open Innovation Achievements Highest Number of Independently Developed Innovative Products among Korean Biopharmaceutical Companies.
_26+_Highest Number of Breakthrough New Drug Pipelines in Korea
_4.5Trillion won_Cumulative RnD Investment
_ AAA in CP Rating_First and Only among participating companies in Korea
- Hanmi is a Pioneer
No path started as a path. Today Hanmi became the protagonist in the development history of the Korean biopharmaceutical industry.
First, Most, and Largest are the indicators that compress the key performance of Hanmi, overwhelming the indutry.
Satellite Symposium
Lunchtime Activities
A Paradigm Shift in Dyslipidemia Treatment
Organized by CVRF and Supported by Educational Grant From Hanmi Pharmaceutical Co., Ltd.
Thursday, April 30
12:20 PM ~ 1:20 PM * KST (UTC/GMT +9:00)
Room 209, Level 2
Moderator(s): Yunseok Choi, Jung-Sun Kim
Panelist(s): Dae-Won Kim, Junghoon Lee
| 12:20 PM | Beyond the Statin, ROSUZET; Start Early, Switch Now Lecturer: Gyu Chul Oh |
| 12:50 PM | Discussion |
Lunchtime Activities
A New Paradigm for Initial Treatment of Hypertension
Organized by CVRF and Supported by Educational Grant From Hanmi Pharmaceutical Co., Ltd.
Saturday, May 2
12:20 PM ~ 1:20 PM * KST (UTC/GMT +9:00)
Presentation Theater 2, Level 1
Moderator(s): Jin Bae Lee, Wook Bum Pyun
| 12:20 PM | Which Patients Benefit From Ultra–Low-Dose Triple Fixed-Dose Combination Therapy? Lecturer: Jong-Young Lee |
| 12:50 PM | Discussion |

